Rekvina Laboratories announced updated timelines for an open offer. Acquirers Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel plan to buy 26% of the company at ₹10 per share. This offers an exit for existing shareholders.
Rekvina Laboratories Open Offer Timeline Updated
Rekvina Laboratories Ltd has issued a corrigendum, updating the key dates for its open offer. Acquirers Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel are set to acquire up to 2,890,100 equity shares, representing 26% of the expanded capital, at ₹10 per share. This follows a Share Purchase Agreement dated March 16, 2026.
What Just Happened
The company has clarified the schedule for its open offer. The tendering period, where shareholders can offer their shares, will commence on July 1, 2026, and close on July 14, 2026. The last date for payment, acceptance, or return of shares is July 28, 2026, with a post-offer public announcement due by August 4, 2026.
Why This Matters
This open offer provides an exit route for existing public shareholders at a price of ₹10 per share. The acquisition signifies a change in control, which could lead to shifts in the company's management and strategic direction.
The Backstory
The open offer was initiated following a Share Purchase Agreement on March 16, 2026. The Committee of Independent Directors has reviewed the offer and deemed it fair and reasonable.
What Changes Now
Shareholders now have a clear timeline to decide whether to participate in the open offer. They can tender their shares through their brokers within the specified dates if they wish to exit their investment at the offer price.
Risks to Watch
Shareholders need to carefully consider if tendering their shares at ₹10 is the best option, weighing it against the potential future performance of the company under new ownership.
Context Metrics
- Offer Size: 2,890,100 Equity Shares
- Offer Price: ₹10 per share
- Percentage of Expanded Capital: 26%
- Offer Opening Date: July 1, 2026
- Offer Closing Date: July 14, 2026
What to Track Next
Investors should monitor exchange filings for any further updates during the tendering period and consider their personal investment strategy based on the offer price and potential future prospects of Rekvina Laboratories.